BVF INC/IL
CIK 1056807 · last filed 2026-09-18
BVF INC/IL is a corporate insider who has filed 39 SEC Form 4 insider transactions across 26 companies since 2008. The most recent filing, for IMUX, was dated Sep 18, 2026. Across all open-market trades the lifetime net is +$10.1M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $2.19B across reported positions. The firm reports its address in San Francisco, CA. 515 SEC filings were submitted jointly with BVF PARTNERS L P/IL.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
LGND price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
40TH FL
SAN FRANCISCO, CA 94104
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IMUX | Director | 42,762 | $7.28 | $311.3K | $0 | 1 | 2026-09-18 |
| MLTX | Director | 6,599,722 | $11.81 | $77.94M | $0 | 1 | 2026-06-22 |
| XOMA Royalty Corp (XOMAP) Delisted | 10%+ Owner | 3,545,545 | $24.98 | $88.57M | $0 | 2 | 2026-05-18 |
| OLMA | Director | 2,103,522 | $6.62 | $13.93M | $0 | 1 | 2025-06-13 |
| ELDN | 10%+ Owner | 2,633,679 | $2.21 | $5.82M | $0 | 1 | 2024-10-31 |
| KYMR | Director | 294,632 | $114.84 | $33.84M | $41.50M | 2 | 2024-01-09 |
| Third Harmonic Bio, Inc. (THRD) Delisted | 10%+ Owner | 2,332,638 | $5.38 | $12.55M | $8.79M | 1 | 2022-12-22 |
| CTI BIOPHARMA CORP (CTIC) Delisted | 10%+ Owner | 1,784,461 | $9.09 | $16.22M | $133.00M | 2 | 2022-03-11 |
| CYTK | 2,760,185 | $60.73 | $167.63M | -$77.57M | 1 | 2020-12-11 | |
| Merus N.V. (MRUS) Delisted | 10%+ Owner | 2,200,035 | $90.00 | $198.00M | $17.24M | 1 | 2020-09-17 |
| IDYA | 10%+ Owner | 1,204,981 | $32.88 | $39.62M | $337.0K | 1 | 2020-07-02 |
| Calithera Biosciences, Inc. (CALA) Delisted | 10%+ Owner | 32,927 | $0.00 | $10 | $3.03M | 1 | 2019-11-18 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | 10%+ Owner | 2,958,503 | $38.00 | $112.42M | $27.11M | 1 | 2019-11-07 |
| PALVELLA THERAPEUTICS, INC. (PIRS) Delisted | 10%+ Owner | 9,654 | $13.60 | $131.3K | $0 | 1 | 2019-02-01 |
| XOMA Royalty Corp (XOMA) Delisted | 10%+ Owner | 355,527 | $40.17 | $14.28M | $6.28M | 1 | 2018-12-10 |
| XENE | 10%+ Owner | 297,464 | $35.77 | $10.64M | $1.82M | 1 | 2017-06-30 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | 10%+ Owner | 3,627,610 | $0.04 | $162.2K | $6.94M | 1 | 2016-12-30 |
| LGND | 10%+ Owner | 2,008,834 | $308.30 | $619.32M | -$303.29M | 4 | 2013-11-29 |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | 10%+ Owner | 4,555,829 | — | — | $2.95M | 1 | 2013-08-02 |
| CAPS | 10%+ Owner | 117 | $2.61 | $305 | $446.7K | 1 | 2011-07-18 |
| Celera CORP (CRA) Delisted | 10%+ Owner | 38,163,934 | — | — | $167.43M | 2 | 2011-05-17 |
| DYNAVAX TECHNOLOGIES CORP (DVAX) Delisted | 10%+ Owner | 1,179,292 | $15.50 | $18.28M | -$5.05M | 3 | 2009-08-03 |
| RPRX | 10%+ Owner | 2,740,026 | $64.76 | $177.44M | -$7.29M | 1 | 2009-07-15 |
| RGEN | 10%+ Owner | 5,795,100 | $180.17 | $1.04B | -$14.95M | 1 | 2009-07-08 |
| EPIRUS Biopharmaceuticals, Inc. (CRXX) Delisted | 10%+ Owner | 8,308,999 | — | — | $251.8K | 2 | 2008-11-25 |
| AVIGEN INC \DE (AVGN) Delisted | 10%+ Owner | 8,055,315 | — | — | $1.12M | 1 | 2008-11-13 |
Recent Filings
39 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-18 | IMUX | Grant (A) | — | $0 | EDGAR |
| 2026-06-22 | MLTX | Grant (A) | — | $0 | EDGAR |
| 2026-05-18 | XOMA Royalty Corp (XOMAP) Delisted | Conv (C) | +50,030,000 | $201.62M | EDGAR |
| 2025-06-13 | OLMA | Grant (A) | — | $0 | EDGAR |
| 2024-10-31 | ELDN | Buy (P) | — | $0 | EDGAR |
| 2024-01-09 | KYMR | Buy (P) | — | $0 | EDGAR |
| 2022-12-22 | Third Harmonic Bio, Inc. (THRD) Delisted | Buy (P) | +2,140,630 | $8.79M | EDGAR |
| 2022-05-31 | KYMR | Buy (P) | +2,894,260 | $41.50M | EDGAR |
| 2022-03-11 | CTI BIOPHARMA CORP (CTIC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-05-21 | XOMA Royalty Corp (XOMAP) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.